Does Takeda Pharmaceutical Company support Israel?

Takeda Pharmaceuticals International GmbH established wholly owned subsidiary Takeda Israel Ltd., headquartered in the Tel Aviv area, to handle sales and marketing of products from Takeda's portfolio and pipeline with an initial focus on oncology — one of six new sales entities Takeda opened in 2013 to reinforce its growth-market platform. Takeda Israel also scouts local partners for in-licensing and distribution, and Takeda's business-development arm actively seeks partnerships with Israeli biotech companies.

Takeda is a founding partner — alongside Johnson & Johnson Innovation and venture firm OrbiMed — of FutuRx, a biotech incubator at the Weizmann Science Park in Ness Ziona that identifies and funds early-stage Israeli biotech startups; roughly $2 million in initial funding came mostly from Israel's Office of the Chief Scientist, with the corporate partners providing the rest plus hands-on drug-development support. Its first companies, Hepy Biosciences and XoNovo, were announced in January 2015.

Formed the Teva Takeda Yakuhin joint venture in Japan with Israel's Teva Pharmaceutical Industries — Teva holding 51% and Takeda 49% — combining Teva's generics portfolio and supply chain with Takeda's Japanese brand and distribution strength. The venture ran for nearly a decade; in December 2024 Teva announced the agreed divestiture of the business to JKI (a fund vehicle of J-Will), expected to complete by April 1, 2025, ending the partnership.